<DOC>
	<DOCNO>NCT00424788</DOCNO>
	<brief_summary>Natalizumab ( TYSABRI ) protein-based drug manufacture Biogen Idec partnership Elan Pharmaceuticals . Natalizumab approve US Europe treatment Multiple Sclerosis ( MS ) . The purpose study determine whether amount natalizumab ( TYSABRI ) present blood ( plasma ) reduce eliminate separate remove plasma replace fluid , process call plasma exchange .</brief_summary>
	<brief_title>A Multicenter Study Assess Effect Plasma Exchange Accelerating Clearance Natalizumab Subjects With Multiple Sclerosis ( MS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>consider Investigator free sign symptom suggestive serious opportunistic infection willing discontinue remain free concomitant immunosuppressive immunomodulatory treatment ( include interferon beta glatiramer acetate ) duration study willing able comply site 's plasma exchange protocol may require hospitalization daily visit consider Investigator immunocompromised history , available abnormal laboratory result indicative major disease would preclude administration recombinant humanize antibody immunomodulating agent duration study . condition ( ) consider contraindication ( ) plasma exchange , include limited bleeding diathesis , hypotension , vascular access limitation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>multiple sclerosis ( MS )</keyword>
</DOC>